Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Savara Inc.NASDAQ: SVRA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $38.92M rose 41.4% year over year, behind the +53.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 16.6% from the prior quarter. Over 3 fiscal years it compounded at +124.1% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +41.4% toward the trailing-twelve-month pace of +53.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$38.92M+16.6% QoQ
Last fiscal yearDec 2025
$123.3M+389.9% YoY
LTMMar 2026
$133.62M+53.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.4%——
1 year+389.9%——
3-year CAGR+124.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
123.3M USD
Year-over-year change
+389.9%
4-year CAGR
+77.3%

Operating Expenses vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's LTM Mar 2026 operating expenses of $133.62M is the highest of the 2 companies compared; the peer median is $88.14M.
  • Its year-over-year change of +53.1% is the highest of 2, against a peer median of +17.0%.
  • Over three fiscal years its annual growth of +124.1% compares with a peer median of +13.0%.
SVRA Competitors Peer median
Operating Expenses for SVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVRASavara Inc.LTM Mar 2026$133.62M +53.1%+124.1%—
TBPHTheravance Biopharma, Inc.LTM Mar 2026$88.14M +17.0%+13.0%80.3%
APMDApnimed, Inc.—— ———
Peer median (excluding SVRA) $88.14M+17.0%+13.0%80.3%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue28.99M27.88M44.26M78.03M245K
Gross Profit(28.99M)(27.88M)(44.26M)(78.03M)(245K)
Gross Margin—————
Research & Development28.99M27.88M44.26M78.03M81.4M
Selling, General & Admin12.35M10.93M15.67M25.04M42.06M
Operating Expenses12.49M10.96M15.75M25.17M123.3M
Depreciation & Amortization136K31K77K130K245K
EBITDA(40.5M)(38.01M)(59.13M)(102.27M)(118.59M)
EBITDA Margin—————
Operating Income(41.48M)(38.84M)(60.01M)(103.2M)(123.55M)
Operating Margin—————
Interest Income2.28K884.44M6.47M4.16M
Interest Expense2.28M88K000
Other Income / Expenses(1.54M)689K5.31M7.32M4.71M
Income Before Tax(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Net Margin—————
EPS (Basic)(0.32)(0.25)(0.33)(0.48)(0.53)
EPS (Diluted)(0.32)(0.25)(0.33)(0.48)(0.53)
Weighted Avg Shares133.92M152.77M165.2M198.19M222.39M
Weighted Avg Shares (Diluted)133.92M152.77M165.2M198.19M222.39M

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.